DRUG · Mapped RxNorm record
Alpelisib
Normalized identity: alpelisibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
NCT05101564
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Tamoxifen
Normalized identity: tamoxifenView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Zotatifin
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Fulvestrant
Normalized identity: fulvestrantView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedUmbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
HER2-negative Breast Cancerunresolved
ER Positive Breast Cancerunresolved
Interventions
AlpelisibDRUG · verified · RxNorm: alpelisib
TamoxifenDRUG · verified · RxNorm: tamoxifen
ZotatifinDRUG
FulvestrantDRUG · verified · RxNorm: fulvestrant
Sponsors & collaborators
Jennifer Lee Caswell-Jinlead sponsor
United States Department of Defensecollaborator
Novartis Pharmaceuticalscollaborator
Effector Therapeuticscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05101564 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.